Subscribe To

Price Alert Latest News Economic Calendar News

CYTO / Altamira's Bentrio Nasal Spray Approved In Malaysia

The Medical Device Authority of Malaysia has approved Altamira Therapeutics Ltd's (NASDAQ: CYTO) Bentrio. "We are very pleased with the swift 'go-to-market' progress in Malaysia and Singapore," commented Thomas Meyer, Founder, Chairman, and CEO. Read More

Demo Live Account See Partner Details

Content Topics

Altamira

Bentrio

Nasal

Spray

Approved

Malaysia

Altamira s

Stock

CYTO

Posted: Jan 21 2022, 10:30

Author Name: Benzinga

CYTO News

By InvestorPlace
November 3, 2023

Why Is Altamira Therapeutics (CYTO) Stock Up 28% Today?

Altamira Therapeutics (NASDAQ: CYTO ) stock is rising higher on Friday despite a lack of news from the biopharmaceutical company. There are no new pr

By Seeking Alpha
September 12, 2023

Altamira Therapeutics Ltd. (CYTO) Q2 2023 Earnings Call Transcript

Altamira Therapeutics Ltd. (NASDAQ:CYTO ) Q2 2023 Earnings Conference Call September 12, 2023 8:00 AM ET Company Participants Thomas Meyer - Founder,

By Seeking Alpha
May 18, 2023

Altamira Therapeutics Ltd. (CYTO) Q4 2022 Earnings Call Transcript

Altamira Therapeutics Ltd. (NASDAQ:CYTO ) Q4 2022 Earnings Conference Call May 16, 2023 8:00 AM ET Company Participants Thomas Meyer - Founder, Chairm

By InvestorPlace
May 4, 2023

Why Is Altamira Therapeutics (CYTO) Stock Up 45% Today?

Altamira Therapeutics (NASDAQ: CYTO ) stock is taking off on Thursday despite a lack of news from the RNA-based therapeutics company. There are no new

By Accesswire
May 1, 2023

Altamira Therapeutics CEO & Chairman to Present at Sidoti Micro-Cap Virtual Conference May 10-11

HAMILTON, BERMUDA / ACCESSWIRE / May 1, 2023 / Altamira Therapeutics ("Altamira" or the "Company") (Nasdaq:CYTO), a company dedicated to developing th

By InvestorPlace
April 12, 2023

Why Is Altamira Therapeutics (CYTO) Stock Up 64% Today?

Altamira Therapeutics (NASDAQ: CYTO ) stock is taking off on Wednesday after providing an update on its SemaPhore nanoparticle technology. According t

By Accesswire
February 14, 2023

Altamira Therapeutics to Report Bentrio Clinical Data, in House Dust Mite and Grass Pollen Allergic Rhinitis, at Feb. 25 AAAAI Annual Meet-ing

House dust mite study shows statistically significant reduction in symptoms vs. no protection Grass pollen study shows faster onset of action and supe

By Accesswire
February 7, 2023

Altamira Therapeutics to Present at Two Upcoming RNA Therapeutics Conferences in Q1 2023

New, trends and future of RNA-based therapeutics Company's OligoPhoreTM / SemaPhoreTM polyplexes provide for efficient delivery of siRNA payloads into

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.